In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.
Ultra-high dose rate radiotherapy—commonly referred to as FLASH radiotherapy—represents a paradigm shift in cancer treatment. By delivering radiation doses within fractions of a second, this modality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results